Home Page

Action required: Please refresh your browser

We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.

More details about this topic are available here »

Revolution Medicines to Participate in Upcoming Investor Conferences

By: GlobeNewswire - 01 Feb 2024

Back to overview list

REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will be a featured speaker at the Guggenheim Healthcare Talks 6^th Annual Biotechnology Conference and the TD Cowen 44^th Annual Health Care Conference.

Details of the company’s participation are as follows:

Guggenheim Healthcare Talks 6^th Annual Biotechnology Conference
Conference Dates: February 7-8, 2024
Fireside Chat Time/Date: 3:00 p.m. Eastern on Wednesday, February 7, 2024
Location: New York, NY; webcast available

TD Cowen 44^th Annual Health Care Conference
Conference Dates: March 4-6, 2024
Fireside Chat Time/Date: 2:10 p.m. Eastern on Wednesday, March 6, 2024
Location: Boston, MA; webcast available

To access the live webcasts of the presentations, please visit the “Events & Presentations” page of Revolution Medicines’ website at https://ir.revmed.com/events-and-presentations. Additionally, replays of the webcasts will be available on the “Events & Presentations” page of the Revolution Medicines website for at least 14 days following each conference.

About Revolution Medicines, Inc.
Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS companion inhibitors for use in combination treatment strategies. The company’s RAS(ON) inhibitors RMC-6236, a RAS(ON) multi-selective inhibitor, RMC-6291, a RAS(ON) G12C-selective inhibitor, and RMC-9805, a RAS(ON) G12D-selective inhibitor, are currently in clinical development. Additional RAS(ON) mutant-selective inhibitors in the company’s development pipeline include RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C).

CONTACT: Revolution Medicines Media & Investor Contact:
Erin Graves
650-779-0136
egraves@revmed.com

Related companies:

Revolution Medicines, Inc.

Back to overview list

to the top ↑